
TELUS Digital reports first quarter 2025 results, with revenue and profitability in line with expectations; management reiterates 2025 outlook
VANCOUVER, British Columbia--(BUSINESS WIRE)--TELUS Digital Experience (TELUS Digital) (NYSE and TSX: TIXT), a leading global technology company specializing in digital customer experiences, today released its results for the three-month period ended March 31, 2025. TELUS Corporation (TSX: T, NYSE: TU) is the controlling shareholder of TELUS Digital. All figures in this news release, and elsewhere in TELUS Digital disclosures, are in U.S. dollars, unless specified otherwise, and relate only to TELUS Digital results and measures.
'In the first quarter of 2025, TELUS Digital's operating and financial results were in line with expectations and support our reiteration of the full-year outlook,' said Jason Macdonnell, Acting Chief Executive Officer and Chief Operating Officer, TELUS Digital and President, Customer Experience. 'Our relationship with TELUS Corporation as an anchor client as well as our overall service diversification continue to provide a certain level of insulation and stability in the current environment. We will continue to invest in and evolve our market and technology capabilities to the benefit of our clients in our pursuit to be the partner of choice as our clients navigate today's business challenges.'
Tobias Dengel, President of TELUS Digital Solutions added, 'In Digital Solutions, similar to other players in our industry, we're closely monitoring client sentiment trends during the recent period of market volatility. At the same time, we are seeing good engagement with clients on their automation and cost efficiency needs. Focusing on the longer term, we believe the demand for transformation of consumer-facing digital experiences should provide a solid basis for our future growth. We are encouraged that our positioning as a differentiated partner in helping our clients innovate their customer journeys resulted in the first quarter's year-over-year growth in Digital Solutions revenues.'
Gopi Chande, Chief Financial Officer said, 'Across TELUS Digital's service lines, in the first quarter of 2025 we achieved year-over-year revenue growth, primarily driven by AI & Data Solutions as well as Digital Solutions. We saw growth among the majority of our top five largest clients in the quarter, on both a sequential and year-over-year basis. Our continued targeted efficiency programs and measured approach to the timing of our investments are yielding solid and growing cost reduction results. As part of reiterating our full-year financial outlook, we are committed to delivering on expectations and achieving a gradual improvement in our performance, while we navigate a fluid macroeconomic backdrop and continue to manage our client concentration.'
Provided below are financial and operating highlights that include certain non-GAAP measures and ratios. See the Non-GAAP section of this news release for a discussion on such measures and ratios.
Q1 2025 vs. Q1 2024 summary
Revenue of $670 million, an increase of $13 million or 2% on a reported basis and 3% on a constant currency basis 1, primarily driven by growth in services provided to existing clients, including TELUS and a leading social media client, among others, and new clients added since the same period in the prior year, partially offset by lower revenues from certain technology and eCommerce clients. Total revenue increase in the quarter included an unfavorable foreign currency impact of approximately 1% compared with the same quarter of the prior year, associated with the strengthening U.S. dollar exchange rate against the euro.
Net loss of $25 million and diluted EPS of $(0.09), compared with net income of $28 million and diluted EPS of $0.05, respectively, in the same quarter of the prior year, due to an increase in operating expenses outpacing revenue growth and other income recognized in the comparative period arising from changes in business combination-related provisions that did not reoccur in the current period, partially offset by lower income taxes and interest expense. Net loss margin, calculated by dividing net loss by revenue for the period, was 3.7%, compared with net income margin of 4.3% for the same quarter in the prior year. Net loss and diluted EPS include the impact of acquisition and integration charges, amortization of purchased intangible assets and interest accretion on written put options, among other items. Adjusted Net Income 1, which excludes the impact of such items, was $17 million, compared with $65 million in the same quarter of the prior year, primarily due to higher salaries and benefits, goods and services purchased, and share-based compensation expense, which were partially offset by higher revenues earned and lower income tax expense.
Adjusted EBITDA 1 was $90 million, compared with $153 million in the same quarter of the prior year, primarily due to the increases in salaries and benefits and goods and services purchased outpacing revenue growth, as well as other income generated in the prior year's comparative period from changes in business combination-related provisions, and higher share-based compensation in the current period. Adjusted EBITDA Margin 1 was 13.4%, compared with 23.3% in the same quarter of the prior year, due to the aforementioned factors. Adjusted Diluted EPS 1 was $0.06, compared with $0.22 in the same quarter of the prior year.
Cash provided by operating activities was $69 million and Free Cash Flow 1 was $41 million, compared with $126 million and $107 million, respectively, in the same quarter of the prior year, primarily due to increases in operating expenses outpacing revenue growth, higher capital expenditures and timing of certain large client payments.
Net Debt to Adjusted EBITDA Leverage Ratio 1 as per our credit agreement was 3.4x as of March 31, 2025 compared with 3.2x as of December 31, 2024.
Team member count was 78,424 as of March 31, 2025, an increase of 5% year-over-year, resulting from the expansion and ramp of our service programs and new wins across our various regions.
A discussion of our results of operations is included in our Management's Discussion and Analysis for the three-month period ended March 31, 2025, which is filed on SEDAR+ and as Exhibit 99.2 to our Form 6-K filed on EDGAR. Such materials and additional information are also provided at telusdigital.com/investors.
Outlook
For the full-year 2025, management continues to expect:
Revenue growth of approximately 2% on an organic basis
Adjusted EBITDA of approximately $400 million
Adjusted Diluted EPS of approximately $0.32
Q1 2025 investor call
TELUS Digital will host a conference call today, May 9, 2025 at 10 a.m. (ET) / 7 a.m. (PT), where management will review the first quarter results, followed by a question and answer session with pre-qualified analysts. A webcast of the conference call will be streamed live on the TELUS Digital Investor Relations website at: https://www.telusdigital.com/investors/news-events and a replay will also be available on the website following the conference call.
Non-GAAP
This news release includes non-GAAP financial information, with reconciliation to GAAP measures presented at the end of this news release. We report certain non-GAAP measures used in the management analysis of our performance, but these do not have standardized meanings under International Financial Reporting Standards, as issued by the International Accounting Standards Board (IFRS ® Accounting Standards). These non-GAAP financial measures and non-GAAP ratios may not be comparable to GAAP measures or ratios and may not be comparable to similarly titled non-GAAP financial measures or non-GAAP ratios reported by other companies, including those within our industry and TELUS Corporation, our controlling shareholder.
Adjusted EBITDA, Adjusted Net Income (Loss), Free Cash Flow, revenue on a constant currency basis, and Net Debt are non-GAAP financial measures, while Adjusted EBITDA Margin, Adjusted Diluted EPS, revenue growth on a constant currency basis and Net Debt to Adjusted EBITDA Leverage Ratio are non-GAAP ratios.
Adjusted EBITDA is commonly used by our industry peers and provides a measure for investors to compare and evaluate our relative operating performance. We use it to assess our ability to service existing and new debt facilities, and to fund accretive growth opportunities and acquisition targets. In addition, certain financial debt covenants associated with our credit facility, including Net Debt to Adjusted EBITDA Leverage Ratio, are based on Adjusted EBITDA, which requires us to monitor this non-GAAP financial measure in connection with our financial covenants. Adjusted EBITDA should not be considered an alternative to net income in measuring our financial performance, and it should not be used as a replacement measure of current and future operating cash flows. However, we believe a financial measure that presents net income adjusted for these items provides a more consistent measure for management to evaluate period-over-period performance and would enable an investor to better evaluate our underlying business trends, our operational performance and overall business strategy.
We exclude items from Adjusted Net Income (Loss) and Adjusted EBITDA, such as acquisition, integration and other, foreign exchange gains or losses and, additionally, with respect to Adjusted Net Income (Loss), the interest accretion on written put options, amortization of purchased intangible assets, and the related tax effect of these adjustments. Full reconciliations of Adjusted EBITDA and Adjusted Net Income (Loss) to the comparable GAAP measures are included at the end of this news release.
We calculate Free Cash Flow by deducting capital expenditures from our cash provided by operating activities, as we believe capital expenditures are a necessary ongoing cost to maintain our existing productive capital assets and support our organic business operations. We use Free Cash Flow to evaluate the cash flows generated from our ongoing business operations that can be used to meet our financial obligations, service debt facilities, reinvest in our business, and to fund, in part, potential future acquisitions.
Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by consolidated revenue. We regularly monitor Adjusted EBITDA Margin to evaluate our operating performance compared to established budgets, operational goals and the performance of industry peers.
Adjusted Diluted EPS is used by management to assess the profitability of our business operations on a per share basis. We regularly monitor Adjusted Diluted EPS as it provides a more consistent measure for management and investors to evaluate our period-over-period operating performance, to better understand our ability to manage operating costs and to generate profits. Adjusted Diluted EPS is calculated by dividing Adjusted Net Income (Loss) by the weighted average number of diluted equity shares outstanding during the period.
Revenue on a constant currency basis is used by management to assess revenue, the most directly comparable GAAP measure, excluding the effect of foreign currency fluctuations. Revenue on a constant currency basis is calculated as current period revenue translated using average foreign exchange rates in the comparable prior period.
Revenue growth on a constant currency basis is used by management to assess the growth of revenue, the most directly comparable GAAP measure, excluding the effect of foreign currency fluctuations. Revenue growth on a constant currency basis is calculated as current period revenue growth translated using average foreign exchange rates in the comparable prior period.
Net Debt to Adjusted EBITDA Leverage Ratio as per our credit agreement is calculated based on Net Debt and Adjusted EBITDA, both as per our credit agreement. Over the long term, we seek to maintain a Net Debt to Adjusted EBITDA Leverage Ratio in the range of 2-3x. We may deviate from our target Net Debt to Adjusted EBITDA Leverage Ratio as per our credit agreement to pursue acquisitions and other strategic opportunities that may require us to borrow additional funds and, additionally, our ability to maintain this targeted ratio depends on our ability to continue to grow our business, general economic conditions, industry trends and other factors.
We have not provided a quantitative reconciliation of our full-year 2025 outlook for Adjusted EBITDA and Adjusted Diluted EPS to our full-year 2025 outlook for net income and diluted EPS because we are unable, without making unreasonable efforts, to calculate certain reconciling items with confidence, which could materially affect the computation of these financial ratios and measures.
Cautionary note regarding forward-looking statements
This news release contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim', 'anticipate', 'assume', 'believe', 'contemplate', 'continue', 'could', 'due', 'estimate', 'expect', 'goal', 'intend', 'may', 'objective', 'plan', 'predict', 'potential', 'positioned', 'seek', 'should', 'target', 'will', 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.
These forward-looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management's beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise, except as required by law.
Specifically, we made several assumptions underlying our financial outlook for the full-year 2025 results, including key assumptions in relation to: our ability to execute our growth strategy, including by expanding services offered to existing clients and attracting new clients; our ability to maintain the competitiveness of our service offerings and meet changing customer needs, including by continuing to invest in, develop and deploy new technologies and digital transformation capabilities; our ability to maintain our corporate culture and attract and retain talent; our ability to integrate, and realize the benefits of, acquisitions that align with our strategy and enhance our core capabilities and solutions; the relative growth rate and size of our target industry verticals; our projected operating and capital expenditure requirements; our ability to manage costs and adjust our cost structure as needed; and the impact of global conditions on our and our clients' businesses, including macroeconomic uncertainty, inflation, interest rates fluctuations and geopolitical conditions. Our financial outlook provides management's best judgement of how trends will impact the business and may not be appropriate for other purposes.
Risk factors that may cause actual results to differ materially from current expectations include, among other things:
We face intense competition from companies that offer services similar to ours.
Our business and financial results have been and could be adversely affected by a number of global conditions and the effects of these same conditions on our clients' businesses and demand for our services.
Because the majority of our costs is fixed in the short-term, we may experience a delay in our ability to immediately adjust our cost structure in response to prolonged lower client demand.
A limited number of clients account for a significant portion of our revenue and loss of or reduction in business from, or consolidation of, these or any other major clients could have a material adverse effect on our business, financial condition, financial performance and prospects.
Our ability to grow and maintain our profitability could be materially affected if changes in technology, including without limitation generative artificial intelligence (GenAI), and client expectations outpace our service offerings and the development of our internal tools and processes or if we are not able to meet the expectations of our clients.
Our growth prospects are dependent upon attracting and retaining enough qualified team members to support our operations, and competition for talent is intense.
If we cannot maintain our unique culture as we grow, our services, financial performance and business may be harmed.
Our business could be adversely affected if we lose members of our senior management.
We could be unable to successfully identify, complete, integrate and realize the benefits of acquisitions or manage the associated risks.
The unauthorized disclosure of sensitive or confidential client and customer data, through cyberattacks or otherwise, could expose us to protracted and costly litigation, damage to reputation and cause us to lose clients / revenue.
Our business may not develop in ways that we currently anticipate due to negative public reaction to offshore outsourcing, content moderation and proposed legislation or otherwise.
Our policies, procedures and programs to safeguard the health, safety and security of our team members, particularly our content moderation team members, may not be adequate.
Our business would be adversely affected if individuals providing data annotation services through AI Data Solutions were classified as employees (not as independent contractors).
The dual-class structure contained in our articles has the effect of concentrating voting control and the ability to influence corporate matters with TELUS.
TELUS will, for the foreseeable future, control the TELUS Digital board of directors.
The market price of our subordinate voting shares may be affected by low trading volume and the market pricing for our subordinate voting shares may decline as a result of future sales, or the perception of the likelihood of future sales, by us or our shareholders in the public market.
These risk factors, as well as other risk factors that may impact our business, financial condition and results of operation, are also described in our 'Risk Factors' section of our Annual Report available on SEDAR+ and in 'Item 3D—Risk Factors' of our Annual Report on Form 20-F filed on February 13, 2025, and available on EDGAR.
TELUS International (Cda) Inc.
Condensed Interim Consolidated Statements of Financial Position
(unaudited)
As at (millions)
December 31, 2024
ASSETS
Current assets
Cash and cash equivalents
$
137
$
174
Accounts receivable
459
454
Due from affiliated companies
31
16
Income and other taxes receivable
9
8
Prepaid and other assets
56
42
Current portion of derivative assets
12
13
704
707
Non-current assets
Property, plant and equipment, net
465
456
Intangible assets, net
1,351
1,379
Goodwill
1,953
1,926
Derivative assets
—
15
Deferred income taxes
12
12
Other long-term assets
26
26
3,807
3,814
Total assets
$
4,511
$
4,521
LIABILITIES AND OWNERS' EQUITY
Current liabilities
Accounts payable and accrued liabilities
$
317
$
321
Due to affiliated companies
260
231
Income and other taxes payable
71
68
Current portion of provisions
44
7
Current maturities of long-term debt
125
116
Current portion of derivative liabilities
1
2
818
745
Non-current liabilities
Provisions
98
139
Long-term debt
1,365
1,409
Derivative liabilities
2
—
Deferred income taxes
248
256
Other long-term liabilities
28
27
1,741
1,831
Total liabilities
2,559
2,576
Owners' equity
1,952
1,945
Total liabilities and owners' equity
$
4,511
$
4,521
Expand
TELUS International (Cda) Inc.
Condensed Interim Consolidated Statements of Cash Flows
(unaudited)
Three months
Periods ended March 31 (millions)
2025
2024
OPERATING ACTIVITIES
Net (loss) income
$
(25
)
$
28
Adjustments:
Depreciation and amortization
81
79
Interest expense
30
35
Income tax expense
—
9
Share-based compensation
7
1
Changes in business combination-related provisions
—
(29
)
Change in market value of derivatives and other
(10
)
(6
)
Net change in non-cash operating working capital
(7
)
11
Income taxes paid, net
(7
)
(2
)
Cash provided by operating activities
69
126
INVESTING ACTIVITIES
Cash payments for capital assets
(27
)
(22
)
Cash payments for acquisitions
—
(3
)
Cash used in investing activities
(27
)
(25
)
FINANCING ACTIVITIES
Shares issued
1
1
Withholding taxes paid related to net share settlement of equity awards
(2
)
(2
)
Long-term debt issued
150
45
Repayment of long-term debt
(211
)
(94
)
Interest paid on credit facilities
(19
)
(24
)
Cash used in financing activities
(81
)
(74
)
Effect of exchange rate changes on cash and cash equivalents
2
—
CASH POSITION
(Decrease) increase in cash and cash equivalents
(37
)
27
Cash and cash equivalents, beginning of period
174
127
Cash and cash equivalents, end of period
$
137
$
154
Expand
Non-GAAP reconciliations
(unaudited)
Three Months Ended
M arch 31
(millions, except percentages)
2025
2024
Revenue, as reported
$
670
$
657
Foreign exchange impact on current period revenue using prior comparative period's rates
7
(2
)
Revenue on a constant currency basis
$
677
$
655
Revenue growth
2
%
(4
)%
Revenue growth on a constant currency basis
3
%
(5
)%
Expand
Three Months Ended
M arch 31
(millions, except per share amounts)
2025
2024
Net (loss) income
$
(25
)
$
28
Add back (deduct):
Acquisition, integration and other
6
7
Amortization of purchased intangible assets
43
42
Interest accretion on written put options
2
3
Foreign exchange gain
(2
)
(5
)
Tax effect of the adjustments above
(7
)
(10
)
Adjusted Net Income
$
17
$
65
Adjusted Basic Earnings Per Share
$
0.06
$
0.24
Adjusted Diluted Earnings Per Share
$
0.06
$
0.22
Expand
Three Months Ended
M arch 31
(millions, except percentages)
2025
2024
Net (loss) income
$
(25
)
$
28
Add back (deduct):
Acquisition, integration and other
6
7
Depreciation and amortization
81
79
Interest expense
30
35
Foreign exchange gain
(2
)
(5
)
Income tax expense
—
9
Adjusted EBITDA
$
90
$
153
Net (loss) income margin
(3.7
)%
4.3
%
Adjusted EBITDA Margin
13.4
%
23.3
%
Expand
Three Months Ended
M arch 31
(millions)
2025
2024
Cash provided by operating activities
$
69
$
126
Less: capital expenditures
(28
)
(19
)
Free Cash Flow
$
41
$
107
Expand
As at (millions, except for ratio)
March 31,
2025
December 31, 2024
Outstanding credit facility
$
1,245
$
1,284
Contingent facility utilization
7
7
Net derivative liabilities
—
2
Cash balance 1
(137
)
(150
)
Net Debt as per credit agreement
$
1,115
$
1,143
Adjusted EBITDA (trailing 12 months) 2
$
418
$
481
Adjustments required as per credit agreement
$
(90
)
$
(124
)
Net Debt to Adjusted EBITDA Leverage Ratio as per credit agreement
3.4
3.2
Expand
1 Maximum cash balance permitted as a reduction to net debt, as per the credit agreement, is $150 million.
About TELUS Digital
TELUS Digital (NYSE & TSX: TIXT) crafts unique and enduring experiences for customers and employees, and creates future-focused digital transformations that deliver value for our clients. We are the brand behind the brands. Our global team members are both passionate ambassadors of our clients' products and services, and technology experts resolute in our pursuit to elevate their end customer journeys, solve business challenges, mitigate risks, and drive continuous innovation. Our portfolio of end-to-end, integrated capabilities include customer experience management, digital solutions, such as cloud solutions, AI-fueled automation, front-end digital design and consulting services, AI & data solutions, including computer vision, and trust, safety and security services. Fuel iX TM is TELUS Digital's proprietary platform and suite of products for clients to manage, monitor, and maintain generative AI across the enterprise, offering both standardized AI capabilities and custom application development tools for creating tailored enterprise solutions.
Powered by purpose, TELUS Digital leverages technology, human ingenuity and compassion to serve customers and create inclusive, thriving communities in the regions where we operate around the world. Guided by our Humanity-in-the-Loop principles, we take a responsible approach to the transformational technologies we develop and deploy by proactively considering and addressing the broader impacts of our work. Learn more at: telusdigital.com.
1 Revenue growth on a constant currency basis, Adjusted EBITDA Margin, Adjusted Diluted EPS and Net Debt to Adjusted EBITDA Leverage Ratio are non-GAAP ratios, while Adjusted Net Income, Adjusted EBITDA and Free Cash Flow are non-GAAP financial measures. See the Non-GAAP section of this news release.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Luxury Real Estate Brokerage Rocked By Scandal Gets Surprise Takeover Offer Worth Twice Its Market Value
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Embattled real estate brokerage Douglas Elliman Inc. (NYSE:DOUG) saw its stock price briefly soar to almost twice its market value on May 27 following news of a takeover offer from rival Anywhere Real Estate (NYSE:HOUS), according to Bloomberg. The merger proposal would value the company at over $4 a share. However, Bloomberg reported that Elliman was unlikely to accept the offer, noting that the offer included selling the company's property management business as part of the deal. The proposed purchase would give Anywhere a sizable foothold in some of Douglas Elliman's key markets, including New York and Miami. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Invest Where It Hurts — And Help Millions Heal: Despite brand recognition and being involved in some of the biggest deals of the last few years, including hedge titan Ken Griffin's $238 million record-breaking penthouse purchase at 220 Central Park South, Douglas Elliman has seen its valuation tumble to $190 million from a peak of over $900 million in December 2021, when it was spun off into standalone company by the Vector Group (NYSE:VGR), Bloomberg reported. The biggest issue Douglas Elliman has faced in recent years is the fallout from lawsuits against former high-profile agents Tal and Oren Alexander. Although the brothers left the firm in 2022 to form their brokerage, Official, multiple allegations of rape and sexual assault saw them charged with sex trafficking by federal prosecutors. Their alleged crimes date back to their tenure at Douglas Elliman. According to a federal indictment handed down on Dec. 11, the brothers had conspired in their alleged sex trafficking since 2009. There were other scandals at the brokerage as well. Former CEO Howard Lorber retired last year after disclosing in an internal inquiry that he was intimate with two brokers, Bloomberg reported. Trending: This Jeff Bezos-backed startup will allow you to . Michael S. Liebowitz, Douglas Elliman's current CEO, has focused on implementing austerity measures, according to Bloomberg, and growing the firm's development marketing business. It has borne fruit, with the company reporting $253 million in revenue in the first quarter, a 26.5% year-over-year increase. 'By focusing on high-impact areas like Development Marketing, we're driving growth and reinforcing our position as the leader in the luxury market – delivering our highest first-quarter revenue since 2022 with significant reductions in operating losses,' Liebowitz said in a statement. 'We are optimistic about our trajectory, and we are committed to staying nimble in our core business. With our strong balance sheet as well as continued investment in the agent experience and new technologies, I am confident that we will continue to build long-term growth and enhance stockholder value.' The company recently launched its new digital platform, which includes Elliman Inspirations, an AI-powered home discovery tool that personalizes property searches and facilitates collaboration between agents and clients. Read Next: With Point, you can , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image: Shutterstock This article Luxury Real Estate Brokerage Rocked By Scandal Gets Surprise Takeover Offer Worth Twice Its Market Value originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit